EUVIMEDEUVIMED entdecken
Crossref

Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma

Kyoko Oura, Asahiro Morishita iD, Rie Yano, Takushi Manabe, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Miwa Tatsuta, Takashi Himoto und 2 weitere

Journal of Gastroenterology · 2025

DOI: 10.1007/s00535-025-02239-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Kyoko Oura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Kagawa, 761-0793, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In atezolizumab/bevacizumab (atezo/bev) therapy for unresectable hepatocellular carcinoma (HCC), the tumor immune environment is regulated through vascular endothelial growth factor A (VEGFA) inhibition to maximize immune checkpoint blockade; however, evidence for VEGFA as a biomarker is limited. This study aimed to investigate serum VEGFA and associated microRNAs (miRNAs) as rapid biomarkers and their regulatory mechanisms in the microenvironment of HCC. METHODS: Fifty-four patients with unresectable HCC who were treated with atezo/bev therapy were enrolled and assigned into objective response (OR) and non-OR groups according to the best therapeutic response in 12 weeks using the modified response evaluation criteria in solid tumors. Serum VEGFA levels and associated miRNA expression were compared. Furthermore, the effect of cell transfection with specific miRNA was investigated. RESULT: There was no significant difference in the pre-treatment serum VEGFA levels between the groups; however, the 3-week/pre-treatment ratio of serum VEGFA levels was significantly lower in the OR group than in the non-OR group. The pre-treatment serum levels of 10 miRNAs, especially miR-485-3p involved in VEGFA expression, were higher in the OR group than in the non-OR group and were further elevated after 1-7 days and 3 weeks. MiR-485-3p suppressed HuH-7 migration, enhanced the expression of protein inhibitor of activated (PIA) signal transducer and activator of transcription 3 (STAT3) (PIAS3), and suppressed the expression of phosphorylated STAT3/VEGFA. CONCLUSION: Circulating miR-485-3p is a more sensitive biomarker than VEGFA for the early prediction of therapeutic response in atezo/bev therapy for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsVascular Endothelial Growth Factor AAntineoplastic Combined Chemotherapy ProtocolsHumansBevacizumabMaleBiomarkers, TumorMiddle AgedAntibodies, Monoclonal, HumanizedFemaleAgedSTAT3 Transcription FactorTreatment OutcomeTumor Microenvironment

Stichwörter der Autor:innen

AtezolizumabBevacizumabHepatocellular carcinomaMicroRNAVascular endothelial growth factor

Substanzen

MicroRNAsVascular Endothelial Growth Factor ABevacizumabBiomarkers, TumorAntibodies, Monoclonal, HumanizedVEGFA protein, humanatezolizumabMIRN485 microRNA, humanSTAT3 Transcription FactorSTAT3 protein, human

Autor:innen und Institutionen

  • Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Kagawa, 761-0793, Japan.
  • Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Kagawa, 761-0793, Japan. morishita.asahiro@kagawa-u.ac.jp.
  • Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Takamatsu, Kagawa, Japan.
  • Department of Gastroenterology, KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan.
  • Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Japan.
  • Department of Gastroenterology, Kagawa Saiseikai Hospital, Takamatsu, Japan.

ORCID-Profile: Asahiro Morishita

Zitieren

APA

Oura, K., Morishita, A., Yano, R., Manabe, T., Takuma, K., Nakahara, M., Tadokoro, T., Fujita, K., Mimura, S., Tani, J., Tatsuta, M., Himoto, T., Masaki, T., & Kobara, H. (2025). Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02239-7

Vancouver

Oura K, Morishita A, Yano R, Manabe T, Takuma K, Nakahara M, et al. Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma. Journal of Gastroenterology. 2025. doi:10.1007/s00535-025-02239-7

BibTeX
@article{Oura2025,
  author = {Oura, Kyoko and Morishita, Asahiro and Yano, Rie and Manabe, Takushi and Takuma, Kei and Nakahara, Mai and Tadokoro, Tomoko and Fujita, Koji and Mimura, Shima and Tani, Joji and Tatsuta, Miwa and Himoto, Takashi and Masaki, Tsutomu and Kobara, Hideki},
  title = {Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma},
  journal = {Journal of Gastroenterology},
  year = {2025},
  doi = {10.1007/s00535-025-02239-7}
}
Kostenlos starten →